The Long Shot - Bingham, Kate; Hames, Tim
12,99 €
inkl. MwSt.

Versandfertig in über 4 Wochen
  • Broschiertes Buch

How Covid-19 vaccines went from the laboratory to people's arms - the inside story of an extraordinary national campaign against all oddsThe Sunday Times bestseller On 3 April 2020, Kate Bingham was told that the likelihood of any Covid-19 vaccine working was 15% at best. But on 8 December 2020, the first NHS patient received a vaccine. Now nearly every adult in Britain has had a jab, lockdowns have ended and we can finally live with Covid. What lies behind this staggering success story? From a cottage miles away from Westminster, Bingham juggled vaccine suppliers, Whitehall, the media circus…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
How Covid-19 vaccines went from the laboratory to people's arms - the inside story of an extraordinary national campaign against all oddsThe Sunday Times bestseller On 3 April 2020, Kate Bingham was told that the likelihood of any Covid-19 vaccine working was 15% at best. But on 8 December 2020, the first NHS patient received a vaccine. Now nearly every adult in Britain has had a jab, lockdowns have ended and we can finally live with Covid. What lies behind this staggering success story? From a cottage miles away from Westminster, Bingham juggled vaccine suppliers, Whitehall, the media circus - and her daughter's exams. Political manoeuvring, miscommunications and administrative meddling nearly jeopardised the project. But perseverance paid off. Catapulted into a national crisis, Bingham's eclectic team secured the first vaccine doses administered in the West and saved thousands of lives in the UK as new variants struck. This is an unmissable insider view into how the Vaccine Taskforce beat the odds and delivered the scientific miracle we all waited for.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Autorenporträt
Dame Kate Bingham served as the Chair of the UK Vaccine Taskforce, on a seven-month unpaid secondment, steering a team of experts to deliver the world¿s fastest Covid-19 vaccination programme. She is Managing Partner at life sciences venture capital firm SV Health Investors where she co-leads SV¿s biotech franchise which has a long history of developing transformational new medicines. SV¿s investments have led to the launch of twenty drugs for inflammatory and autoimmune disease, blindness and cancer. At SV, Kate co-manages a number of global biotech venture funds which make investments into innovative companies developing novel therapeutics and she helped launch the Dementia Discovery Fund. She is a board member of the Francis Crick Institute and was awarded a DBE in the Queen¿s Birthday Honours for her services as Chair of the UK Vaccine Taskforce.The author proceeds will be donated to the new university The New Model Institute for Technology and Engineering (NMITE) and early years education, development and advocacy charity Kindred Squared.